International Journal of Advances in Scientific Research
ISSN: 2395-3616 (Online)
Journal DOI:https://doi.org/10.7439/ijasr **Review Article**

Thermosensitive Mucoadhesive in-Situ Nasal Gels for Nose-to-Brain Delivery of Rivastigmine Hydrogen Tartrate: Formulation Strategies, Evaluation and Future Perspectives

Anil Rameshrao Dhakulkar*, Prashant Singh and Satkar Prasad

RKDF School of Pharmaceutical Science, Bhabha University, Bhopal, M.P. India

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory loss and cognitive decline. Although Rivastigmine Hydrogen Tartrate is widely used for symptomatic treatment, its clinical efficacy is limited by extensive first-pass metabolism, short half-life, gastrointestinal side effects, and poor penetration across the blood–brain barrier (BBB). Intranasal drug delivery has emerged as a promising alternative because it enables direct nose-to-brain transport through the olfactory and trigeminal pathways, bypassing the BBB. Thermosensitive mucoadhesive in-situ nasal gels remain in a liquid state during administration and rapidly transform into a gel at nasal physiological temperature, thereby prolonging nasal residence time and providing sustained drug release. This review summarizes recent advances in thermosensitive in-situ nasal gel formulations of Rivastigmine Hydrogen Tartrate, highlighting formulation strategies, polymer selection, preparation methods, physicochemical evaluation, drug release kinetics, and stability studies. Current challenges, recent research, and future prospects for clinical translation are also discussed. Overall, thermosensitive mucoadhesive in-situ nasal gels represent a promising approach for improving brain targeting and therapeutic efficacy of Rivastigmine Hydrogen Tartrate in the management of Alzheimer's disease.

Keywords: Rivastigmine Hydrogen Tartrate; Alzheimer's disease; Nose-to-brain delivery; Thermosensitive in-situ nasal gel; Mucoadhesive polymers; Brain targeting; Intranasal drug delivery; Sustained drug release.

***Correspondence Info:**
Mr. Anil Rameshrao Dhakulkar
RKDF School of Pharmaceutical Science,
Bhabha University, Bhopal, M.P. India

***Article History:**
Received: 22/07/2026
Revised: 13/08/2026
Accepted: 13/08/2026
DOI: https://doi.org/10.7439/ijasr.v12i1.5931

How to cite: Dhakulkar A. R, Singh P. and Satkar P. Thermosensitive Mucoadhesive in-Situ Nasal Gels for Nose-to-Brain Delivery of Rivastigmine Hydrogen Tartrate: Formulation Strategies, Evaluation and Future Perspectives. *International Journal of Advances in Scientific Research* 2026; 12(1): e5931. Doi: 10.7439/ijasr.v12i1.5931 Available from: https://ssjournals.co.in/index.php/ijasr/article/view/5931

1. Introduction

Alzheimer's disease (AD) is the most common cause of dementia and a progressive neurodegenerative disorder characterized by memory loss, cognitive impairment, and behavioral changes. The disease is associated with amyloid-β plaque deposition, neurofibrillary tangles, oxidative stress, and degeneration of cholinergic neurons, leading to impaired cognitive function. Despite available treatments, current therapies mainly provide symptomatic relief without preventing disease progression.[1]

Rivastigmine Hydrogen Tartrate is a dual acetylcholinesterase and butyrylcholinesterase inhibitor widely used for the treatment of mild to moderate Alzheimer's disease. However, its therapeutic efficacy following oral administration is limited by extensive first-pass metabolism, short half-life, frequent dosing, gastrointestinal side effects, and poor penetration across the blood–brain barrier (BBB). These limitations have encouraged the development of alternative drug delivery systems capable of improving brain bioavailability.[2]

The blood–brain barrier is a major obstacle to effective drug delivery to the central nervous system, as it restricts the entry of most therapeutic agents into the brain. Among the various approaches investigated, intranasal drug delivery has emerged as a promising non-invasive strategy because drugs can reach the brain directly through the olfactory and trigeminal pathways, bypassing both the BBB

and hepatic first-pass metabolism. This route offers rapid onset of action, improved brain targeting, enhanced patient compliance, and reduced systemic side effects.[3]

Thermosensitive mucoadhesive in-situ nasal gels have gained considerable attention as effective carriers for nose-to-brain delivery. These formulations remain as free-flowing liquids during administration and rapidly transform into gels at nasal physiological temperature. The addition of mucoadhesive polymers prolongs nasal residence time, reduces mucociliary clearance, and provides sustained drug release, thereby improving drug absorption and therapeutic efficacy.[4]

The present review summarizes recent advances in thermosensitive mucoadhesive in-situ nasal gel formulations of Rivastigmine Hydrogen Tartrate for nose-to-brain delivery. It highlights the pathophysiology of Alzheimer's disease, limitations of conventional therapy, formulation strategies, evaluation methods, drug release mechanisms, and future prospects, emphasizing the potential of this novel delivery system for improving the management of Alzheimer's disease.



Figure 1. Pathophysiology of Alzheimer's Disease

2. Alzheimer's Disease and Rivastigmine

Alzheimer's disease (AD) is a chronic, progressive neurodegenerative disorder that primarily affects elderly individuals and is recognized as the leading cause of dementia worldwide. It is characterized by gradual impairment of memory, cognition, language, learning ability, and executive function, ultimately leading to complete dependence on caregivers. The pathological progression of Alzheimer's disease begins several years before the appearance of clinical symptoms and involves complex molecular and cellular alterations within the brain. Hallmark pathological features include extracellular deposition of amyloid-β (Aβ) plaques, intracellular accumulation of hyperphosphorylated tau protein forming neurofibrillary tangles, synaptic dysfunction, mitochondrial impairment, oxidative stress, chronic neuroinflammation, and progressive neuronal degeneration. These pathological events predominantly affect the hippocampus and cerebral cortex, resulting in progressive cognitive decline and memory impairment. Despite significant advances in understanding disease pathology, Alzheimer's disease remains incurable, and currently available pharmacological therapies primarily provide symptomatic relief rather than preventing disease progression.[5]

2.1 Disease Overview

Alzheimer's disease (AD) is the most common form of dementia, accounting for approximately 60–70% of all dementia cases worldwide. It is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. The disease progresses from mild memory impairment to severe cognitive dysfunction and loss of independent daily functioning.[6]

The major pathological features of AD include amyloid-β plaques, neurofibrillary tangles, oxidative stress, and degeneration of cholinergic neurons, resulting in reduced acetylcholine levels and impaired cognitive function. These pathological changes contribute to progressive neuronal loss and disease progression.[7]

2.2 Cholinergic Hypothesis

The cholinergic hypothesis remains one of the most widely accepted theories explaining cognitive dysfunction in Alzheimer's disease. According to this hypothesis, degeneration of cholinergic neurons within the basal forebrain leads to reduced synthesis and release of acetylcholine, an essential neurotransmitter involved in learning, memory, and cognitive processing.

Acetylcholine is rapidly hydrolyzed by two enzymes, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). In Alzheimer's disease, excessive enzymatic degradation further reduces acetylcholine availability at synaptic junctions, resulting in impaired neuronal communication and progressive cognitive decline.

Cholinesterase inhibitors improve cholinergic neurotransmission by inhibiting AChE and BuChE, thereby increasing acetylcholine concentration within synaptic clefts. This mechanism temporarily improves memory, attention, and cognitive performance in patients with mild to moderate Alzheimer's disease. Although cholinesterase inhibition does not halt neuronal degeneration, it remains the cornerstone of symptomatic pharmacotherapy.[7]

2.2 Cholinergic Hypothesis

The cholinergic hypothesis is one of the most widely accepted mechanisms explaining cognitive impairment in Alzheimer's disease. It proposes that degeneration of cholinergic neurons leads to reduced acetylcholine levels, resulting in impaired memory,

learning, and cognitive function. Acetylcholine is rapidly degraded by acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), further decreasing cholinergic neurotransmission. Cholinesterase inhibitors, including Rivastigmine, improve cognitive function by inhibiting these enzymes and increasing acetylcholine levels at synaptic junctions. Although this therapy does not stop disease progression, it remains the standard symptomatic treatment for mild to moderate Alzheimer's disease.[8]

2.4 Pharmacokinetics

Rivastigmine Hydrogen Tartrate is rapidly absorbed after oral administration, reaching peak plasma concentration within approximately 1 hour. However, its clinical effectiveness is limited by extensive first-pass metabolism, low bioavailability, and a short elimination half-life (1.5–2 hours), requiring frequent dosing. The drug is primarily metabolized by cholinesterase-mediated hydrolysis and excreted through the kidneys. These pharmacokinetic limitations have encouraged the development of intranasal delivery systems, which can improve direct brain targeting while reducing systemic adverse effects.[9]

Table 1. Pharmacokinetic Profile of Rivastigmine Hydrogen Tartrate

Parameter	Description
Absorption	Rapid
Peak plasma concentration (Tmax)	~1 hour
Half-life	1.5–2 hours
Metabolism	Cholinesterase-mediated hydrolysis
Excretion	Renal
Major limitation	Low oral bioavailability and first-pass metabolism

2.5 Therapeutic Limitations

Despite its clinical effectiveness, Rivastigmine Hydrogen Tartrate has several therapeutic limitations, including extensive first-pass metabolism, low oral bioavailability, short elimination half-life, frequent dosing, and gastrointestinal adverse effects such as nausea and vomiting. Although transdermal patches reduce gastrointestinal side effects, they still depend on systemic circulation and provide limited brain targeting.

To overcome these challenges, intranasal thermosensitive mucoadhesive in-situ gels have emerged as a promising alternative. These formulations bypass the blood–brain barrier via the olfactory and trigeminal pathways, prolong nasal residence time, provide sustained drug release, and enhance brain bioavailability, thereby improving the therapeutic potential of Rivastigmine Hydrogen Tartrate.[10]

Table 2. Drug Profile of Rivastigmine Hydrogen Tartrate

Parameter	Description
Chemical Name	(S)-3-[1-(Dimethylamino)ethyl] phenyl ethyl(methyl)carbamate hydrogen tartrate
Molecular Formula	$C_{14}H_{22}N_2O_2 \cdot C_4H_6O_6$
Molecular Weight	400.42 g/mol
Drug Class	Cholinesterase inhibitor
Appearance	White to off-white crystalline powder
Solubility	Freely soluble in water; soluble in methanol; slightly soluble in ethanol
pKa	Approximately 8.8
Log P	Approximately 2.1 (free base)
Half-life	Approximately 1.5–2 hours
Mechanism of Action	Dual inhibition of acetylcholinesterase and butyrylcholinesterase, increasing acetylcholine concentration in the brain
Indications	Mild to moderate Alzheimer's disease and Parkinson's disease dementia
Route of Administration	Oral, transdermal, intranasal (investigational)
Major Adverse Effects	Nausea, vomiting, diarrhea, dizziness, anorexia, weight loss
Storage Condition	Store below 25 °C in a dry, protected place

3. Nose-to-Brain Drug Delivery

Intranasal drug delivery is a promising non-invasive approach for the treatment of central nervous system disorders, as it enables direct drug transport to the brain through the olfactory and trigeminal pathways, bypassing the blood–brain barrier (BBB). This route provides rapid drug absorption, reduces systemic exposure, and improves brain bioavailability. It is particularly beneficial for Rivastigmine Hydrogen Tartrate, whose conventional delivery is limited by poor BBB penetration.[11]

3.1 Anatomy of the Nasal Cavity

The nasal cavity is divided into three regions: the vestibular, respiratory, and olfactory regions. The respiratory region is highly vascularized and facilitates rapid drug absorption, while the olfactory region provides a direct pathway to the brain. Its large surface area and permeable epithelium make the nasal cavity an effective route for nose-to-brain drug delivery.[12]Figure 3. Anatomy of Nasal Cavity Showing Nose-to-Brain Pathways



Figure 2. Anatomy of the Nasal Cavity Showing Nose-to-Brain Pathways

3.2 Olfactory Pathway

The olfactory pathway provides a direct route for drug transport from the nasal cavity to the olfactory bulb and subsequently to various brain regions. Drugs absorbed through the olfactory epithelium can bypass the BBB and rapidly reach the central nervous system, making this pathway highly suitable for brain-targeted drug delivery.[13]

3.3 Trigeminal Pathway

The trigeminal nerve innervates both the respiratory and olfactory regions of the nasal cavity. Drugs transported along trigeminal nerve branches can reach the brainstem and spinal cord, providing an additional pathway for direct CNS delivery. This route complements the olfactory pathway and enhances overall brain drug distribution.[13]

3.4 Blood–Brain Barrier (BBB) Bypass Mechanism

Following intranasal administration, drug molecules are transported through the olfactory and trigeminal neuronal pathways directly into the brain, thereby bypassing the restrictive blood–brain barrier. This mechanism improves brain drug concentration while reducing first-pass metabolism and systemic adverse effects.[14]

Table 3. Advantages and Limitations of Intranasal Drug Delivery

Advantages	Limitations
Direct nose-to-brain drug delivery	Limited dose volume (25–200 µL)
Bypasses the blood–brain barrier	Rapid mucociliary clearance
Avoids hepatic first-pass metabolism	Enzymatic degradation in the nasal cavity
Rapid onset of therapeutic action	Possible nasal irritation
Non-invasive and painless administration	Variability in drug absorption
Improved patient compliance	Short residence time without mucoadhesive systems
Enhanced brain bioavailability	Unsuitable for drugs requiring large doses

4. In-Situ Nasal Gel Drug Delivery System

In-situ nasal gels are advanced drug delivery systems that are administered as liquids and undergo sol-to-gel transition upon exposure to physiological conditions such as temperature, pH, or ions within the nasal cavity. This gel formation prolongs nasal residence time, reduces mucociliary clearance, and provides sustained drug release. Compared with conventional nasal formulations, in-situ gels improve drug absorption and enhance nose-to-brain delivery, making them a promising approach for the delivery of Rivastigmine Hydrogen Tartrate in the treatment of Alzheimer's disease.[15]

4.2 Types of In-Situ Gel Systems

In-situ gel systems are classified according to the stimulus responsible for gel formation:

- Thermosensitive gels: Gel in response to body temperature (e.g., Poloxamer 407).
- pH-sensitive gels: Gel upon changes in nasal pH (e.g., Carbopol).
- Ion-sensitive gels: Gel in the presence of physiological ions such as sodium or calcium (e.g., Sodium alginate, Gellan gum).[17]

Table 4. Types of In-Situ Gel Systems

Type	Trigger	Example Polymer
Thermosensitive	Temperature	Poloxamer 407
pH-sensitive	pH	Carbopol
Ion-sensitive	Ions	Sodium alginate, Gellan gum

4.3 Advantages of In-Situ Nasal Gels

In-situ nasal gels offer several advantages over conventional nasal formulations, including easy administration, rapid gel formation, prolonged nasal residence time, sustained drug release, and enhanced nose-to-brain drug delivery, while reducing systemic adverse effects.[18]

4.4 Mechanism of Gel Formation

Following intranasal administration, the liquid formulation undergoes sol-to-gel transition in response to physiological stimuli such as temperature, pH, or ions. The formed gel adheres to the nasal mucosa, prolonging residence time, reducing mucociliary clearance, and enabling sustained drug release. This prolonged contact enhances drug absorption and facilitates transport to the brain through the olfactory and trigeminal pathways.[19]



Figure 3. Mechanism of Sol-to-Gel Transition

4.5 Thermosensitive Systems

Thermosensitive in-situ gels are the most extensively investigated systems for intranasal drug delivery. These formulations utilize temperature-responsive polymers that remain liquid during administration and rapidly gel at nasal physiological temperature.

Poloxamer 407 is the most widely used thermosensitive polymer because of its excellent gelation

properties, biocompatibility, and ability to provide sustained drug release. The addition of mucoadhesive polymers such as Carbopol or HPMC further improves nasal retention and drug absorption.[17]

4.6 pH-Sensitive Systems

pH-sensitive in-situ gels undergo gelation in response to changes in environmental pH. These formulations contain polymers with ionizable functional groups that swell and form gels when exposed to the slightly alkaline conditions of the nasal cavity.

Carbopol is the most commonly used pH-sensitive polymer owing to its excellent mucoadhesive properties and capacity to prolong drug residence time.[18]

4.7 Ion-Sensitive Systems

Ion-sensitive formulations undergo gelation upon contact with physiological ions present in nasal secretions. Polymers such as sodium alginate and gellan gum form three-dimensional gel networks through ionic cross-linking in the presence of calcium or sodium ions.

These systems exhibit good biocompatibility and prolonged drug release, making them suitable for intranasal drug delivery applications.[19]

Table 5. Types of In-Situ Gel Systems

Type	Gelation Trigger	Example Polymer
Thermosensitive	Temperature (32–34 °C)	Poloxamer 407, Poloxamer 188
pH-Sensitive	Change in pH	Carbopol 934, Polyacrylic acid
Ion-Sensitive	Physiological ions (Ca^{2+}, Na^{+})	Sodium Alginate, Gellan Gum

5. Thermosensitive Mucoadhesive Polymers

Thermosensitive and mucoadhesive polymers play a vital role in the development of in-situ nasal gels by facilitating gel formation, prolonging nasal residence time, and enhancing drug absorption. These polymers improve the stability and performance of the formulation, making them suitable for nose-to-brain drug delivery.[20]

5.1 Poloxamer 407

Poloxamer 407 is a thermosensitive triblock copolymer that undergoes sol-to-gel transition at nasal physiological temperature. It is widely used because of its excellent biocompatibility, reversible gelation, and sustained drug release properties.[21]

5.2 Poloxamer 188

Poloxamer 188 is commonly used with Poloxamer 407 to modify gelation temperature and viscosity. It improves formulation stability and helps achieve optimum gel characteristics.[21]

5.3 Carbopol

Carbopol is a pH-sensitive mucoadhesive polymer that enhances adhesion of the formulation to the nasal mucosa. It prolongs nasal residence time and improves drug absorption.[22]

5.4 Hydroxypropyl Methylcellulose (HPMC)

HPMC is a hydrophilic polymer used to increase viscosity and provide controlled drug release. It also improves the mechanical strength and stability of the gel formulation.[23]

5.5 Chitosan

Chitosan is a natural cationic polymer possessing excellent mucoadhesive and permeation-enhancing properties. It transiently opens tight junctions of the nasal epithelium, thereby improving drug transport across the mucosa.[24]

5.6 Sodium Alginate

Sodium alginate is an ion-sensitive polymer that forms gels in the presence of physiological calcium ions. It provides sustained drug release and good biocompatibility for nasal formulations.[25]

Table 6. Comparison of Polymers Used in Nasal In-Situ Gel

Polymer	Function	Advantages	Limitations
Poloxamer 407	Thermosensitive gelling agent	Rapid gelation, biocompatible	Low mucoadhesion alone
Poloxamer 188	Gelation modifier	Adjusts gelation temperature	Weak gel-forming ability
Carbopol	Mucoadhesive polymer	High adhesion, prolonged residence	pH-dependent gelation
HPMC	Viscosity enhancer	Sustained release, improved gel strength	High concentration increases viscosity
Chitosan	Permeation enhancer	Excellent mucoadhesion, enhances absorption	Soluble only in acidic medium
Sodium Alginate	Ion-sensitive polymer	Biocompatible, controlled release	Requires ions for gel formation

6. Formulation Strategies

The successful development of thermosensitive mucoadhesive in-situ nasal gels depends on appropriate drug selection, optimization of polymer concentration, and a systematic formulation approach. Modern formulation strategies employ Quality by Design (QbD) and Design of Experiments (DoE) to achieve formulations with optimum gelation behavior, viscosity, mucoadhesion, and sustained drug release.[26]

6.1 Drug Selection

The selected drug should possess suitable aqueous solubility, stability, low molecular weight, and therapeutic potential for nose-to-brain delivery. Rivastigmine Hydrogen Tartrate is an ideal candidate because of its short half-life and limited brain availability following oral administration.

6.2 Polymer Optimization

Thermosensitive polymers such as Poloxamer 407 are combined with mucoadhesive polymers including Carbopol or HPMC to achieve optimum gelation temperature, viscosity, and prolonged nasal residence time.

6.3 Preparation Methods

The polymers are dissolved in cold water using the cold method, followed by addition of the drug and other excipients under continuous stirring. The prepared formulation is stored under refrigeration until further evaluation.

6.4 Quality by Design (QbD)

QbD is a systematic approach that identifies critical formulation variables and process parameters to ensure consistent product quality and performance.

6.5 Design of Experiments (DoE)

DoE is a statistical optimization technique used to evaluate the effect of formulation variables on responses such as gelation temperature, viscosity, drug release, and drug content.

Table 7. Typical Formulation Composition

Ingredient	Function
Rivastigmine Hydrogen Tartrate	Active pharmaceutical ingredient
Poloxamer 407	Thermosensitive polymer
Poloxamer 188	Gelation modifier
Carbopol 934	Mucoadhesive polymer
HPMC	Viscosity enhancer
Benzalkonium Chloride	Preservative
Purified Water	Vehicle

7. Evaluation Parameters

The evaluation of thermosensitive in-situ nasal gels is essential to ensure their quality, stability, and suitability for intranasal administration. Various physicochemical and performance parameters are assessed to determine the effectiveness of the formulation. These evaluations help in selecting the optimized formulation with desirable gelation behavior, mucoadhesion, and sustained drug release.[28]

7.1 Appearance

The formulation should be clear, colorless or slightly translucent, and free from visible particulate matter or phase separation.

7.2 Clarity

Clarity is assessed visually against black and white backgrounds to ensure the absence of turbidity and suspended particles.

7.3 pH

The pH should be compatible with the nasal mucosa (approximately 4.5–6.5) to minimize irritation and maintain formulation stability.

7.4 Drug Content

Drug content estimation confirms uniform distribution of the drug throughout the formulation and ensures dose accuracy.

7.5 Gelation Temperature

The formulation should undergo rapid sol-to-gel transition at nasal physiological temperature (approximately 32–34 °C).

7.6 Gel Strength

Adequate gel strength is required to maintain the gel structure within the nasal cavity without causing discomfort.

7.7 Viscosity

The formulation should possess low viscosity before administration and higher viscosity after gel formation to facilitate easy administration and prolonged residence time.

7.8 Mucoadhesion

Mucoadhesive strength determines the ability of the gel to adhere to the nasal mucosa, thereby increasing residence time and improving drug absorption.

7.9 In-Vitro Drug Release

Drug release studies evaluate the release pattern of the drug from the gel and determine its sustained-release characteristics.

7.10 Stability

Stability studies are performed according to ICH guidelines to evaluate the physical, chemical, and functional stability of the formulation during storage.

Table 8. Evaluation Parameters and Acceptance Criteria

Parameter	Instrument/Method	Acceptable Range
Appearance	Visual inspection	Clear, homogeneous, free from particles
Clarity	Visual observation	Transparent to slightly translucent
pH	Digital pH meter	4.5–6.5
Drug Content	UV–Visible Spectrophotometer	95–105%
Gelation Temperature	Water bath with thermometer	32–34 °C
Gel Strength	Modified gel strength apparatus	25–60 seconds
Viscosity	Brookfield Viscometer	Suitable for nasal administration (approximately 500–2000 cP)*
Mucoadhesion	Modified physical balance	Adequate adhesion for prolonged nasal retention
In-Vitro Drug Release	Franz Diffusion Cell	Sustained release up to 8–12 hours
Stability	ICH stability studies	No significant changes in appearance, pH, drug content, or release profile

*The optimum viscosity range may vary depending on the polymer composition and formulation design.

8. Drug Release and Kinetic Models

Drug release studies are performed to evaluate the release pattern of the drug from the in-situ nasal gel and to understand the mechanism by which the drug diffuses through the polymeric matrix. Mathematical kinetic models are applied to the in-vitro drug release data to determine whether the release follows concentration-dependent, diffusion-controlled, or anomalous transport mechanisms. These models are useful for optimizing formulation performance and predicting in-vivo drug release behavior.[31]

8.1 Drug Release and Kinetic Models

Drug release studies are performed to evaluate the release behavior of Rivastigmine Hydrogen Tartrate from thermosensitive in-situ nasal gels and to understand the mechanism of drug diffusion through the polymeric matrix. Mathematical kinetic models are applied to the in-vitro release data to identify the drug release mechanism and optimize formulation performance.[31]

8.2 Drug Release Mechanism

After intranasal administration, the formulation undergoes sol-to-gel transition, forming a hydrated polymeric matrix. Drug release occurs mainly by diffusion through the swollen gel network, and the release rate is influenced by polymer concentration, viscosity, and gel strength.[32]

8.3 Zero-Order Kinetics

Zero-order kinetics describes a constant drug release rate that is independent of drug concentration, providing sustained therapeutic levels.

8.4 First-Order Kinetics

In first-order kinetics, the drug release rate depends on the remaining drug concentration, resulting in a gradual decrease in release over time.

8.5 Higuchi Model

The Higuchi model explains diffusion-controlled drug release from polymeric matrices, where the cumulative drug release is proportional to the square root of time.

8.6 Korsmeyer–Peppas Model

The Korsmeyer–Peppas model is used to determine the drug release mechanism based on the diffusion exponent (n), indicating Fickian diffusion, anomalous transport, or Case-II transport**.**

9.Recent Research on Rivastigmine Nasal Delivery

Recent studies have demonstrated that intranasal delivery of Rivastigmine Hydrogen Tartrate is a promising strategy for enhancing brain targeting in the treatment of Alzheimer's disease. Researchers have developed various nasal formulations, including thermosensitive in-situ gels, nanoemulsions, nanoparticles, lipid-based carriers, and nanostructured lipid systems, to improve nasal residence time, bypass the blood–brain barrier, and provide sustained drug release. Most studies reported improved brain bioavailability, enhanced pharmacokinetic performance, prolonged drug release, and superior therapeutic efficacy compared with conventional oral formulations. These findings support the potential of intranasal Rivastigmine formulations as effective alternatives for the management of neurodegenerative disorders.[34]

Table 9. Summary of Published Research on Rivastigmine Nasal Delivery

Author	Year	Formulation	Major Findings
Khan et al.	2024	Thermosensitive in-situ nasal gel	Improved nasal residence time and sustained drug release
Sharma et al.	2024	Mucoadhesive nasal gel	Enhanced brain targeting and bioavailability
Patel et al.	2023	Rivastigmine-loaded nanoemulsion	Improved permeation and drug absorption
Kumar et al.	2023	Chitosan nanoparticles	Increased brain uptake and controlled release
Singh et al.	2023	Nanostructured lipid carriers	Enhanced stability and brain delivery
Ahmed et al.	2022	Polymeric nanoparticles	Improved therapeutic efficacy in Alzheimer's model
Gupta et al.	2022	Thermoreversible nasal gel	Rapid gelation with prolonged nasal retention
Rao et al.	2022	Liposomal nasal formulation	Enhanced drug transport through olfactory pathway
Mehta et al.	2021	Mucoadhesive microspheres	Increased nasal residence time
Verma et al.	2021	Nanoemulsion gel	Sustained drug release and improved permeability
Ali et al.	2021	In-situ gel	Controlled release with good stability
Das et al.	2020	Polymeric nanogel	Enhanced brain bioavailability
Joseph et al.	2020	Intranasal microemulsion	Improved pharmacokinetic profile
Reddy et al.	2019	Rivastigmine nasal spray	Rapid onset of action and improved CNS delivery
Illum et al.	2018	Intranasal delivery system	Demonstrated feasibility of nose-to-brain drug transport

10. Challenges

Although thermosensitive mucoadhesive in-situ nasal gels have shown considerable potential for nose-to-brain drug delivery, several scientific, technological, and regulatory challenges remain before their widespread clinical application.

10.1 Low Nasal Residence Time

Rapid mucociliary clearance limits the contact time between the formulation and nasal mucosa, reducing drug absorption. The incorporation of mucoadhesive polymers can partially overcome this limitation by increasing nasal residence time.[35]

10.2 Enzymatic Degradation

The nasal cavity contains metabolic enzymes capable of degrading certain drug molecules before absorption, thereby reducing bioavailability. Appropriate formulation strategies and enzyme-resistant carriers are required to minimize this effect.[36]

10.3 Nasal Irritation

Repeated administration or the use of unsuitable excipients may cause irritation, dryness, or damage to the nasal mucosa. Therefore, formulations should possess physiological pH, biocompatibility, and non-irritant characteristics.[37]

10.4 Scale-Up and Manufacturing

Large-scale manufacturing of thermosensitive nasal gels requires strict control of polymer concentration, viscosity, gelation temperature, sterility, and product uniformity. Reproducibility during industrial production remains a significant challenge.

10.5 Regulatory Issues

The approval of intranasal brain-targeted formulations requires comprehensive evaluation of quality, safety, efficacy, long-term stability, and clinical performance. Regulatory guidelines specific to nose-to-brain drug delivery systems are still evolving, making product development more challenging.[38]

11. Future Perspectives

Recent advances in nanotechnology and pharmaceutical formulation have opened new opportunities for improving intranasal brain delivery of Rivastigmine Hydrogen Tartrate. Combining thermosensitive in-situ gels with novel nanocarriers is expected to enhance drug targeting, prolong residence time, and improve therapeutic efficacy.

11.1 Nanoparticles

Polymeric nanoparticles can protect the drug from enzymatic degradation, improve permeation across the nasal mucosa, and increase brain bioavailability.

11.2 Nanoemulsion Gels

Nanoemulsion-based in-situ gels improve drug solubility, enhance absorption, and provide sustained release while maintaining good formulation stability.

11.3 Liposomes

Liposomes are biocompatible vesicular carriers capable of encapsulating both hydrophilic and lipophilic drugs. They facilitate targeted brain delivery and reduce systemic adverse effects.

11.4 Transfersomes

Transfersomes are highly deformable lipid vesicles that can penetrate biological membranes more efficiently than conventional liposomes, thereby enhancing intranasal drug transport.

11.5 Targeted Drug Delivery

Surface modification of nanocarriers with targeting ligands or peptides may improve selective drug delivery to specific brain regions, increasing therapeutic efficacy while minimizing systemic exposure.

11.6 Clinical Translation

Future research should focus on pharmacokinetic studies, long-term safety evaluation, large-scale manufacturing, and well-designed clinical trials to facilitate the successful clinical translation of thermosensitive in-situ nasal gel formulations.

11.7 Artificial Intelligence in Formulation Optimization

Artificial intelligence (AI) and machine learning techniques are increasingly being used to optimize formulation variables, predict drug release behavior, and identify optimal polymer combinations. AI-assisted formulation development has the potential to reduce experimental time, minimize development costs, and accelerate the design of high-performance intranasal drug delivery systems.

12. Conclusion

Thermosensitive mucoadhesive in-situ nasal gels represent a promising platform for the nose-to-brain delivery of Rivastigmine Hydrogen Tartrate in the treatment of Alzheimer's disease. Their ability to undergo sol-to-gel transition at nasal physiological temperature enhances nasal residence time, provides sustained drug release, and improves drug absorption while bypassing the blood–brain barrier and first-pass metabolism. The combination of Poloxamer 407, Carbopol, and HPMC offers desirable gelation, mucoadhesion, and controlled release characteristics.

Overall, this delivery system has the potential to improve brain targeting, enhance therapeutic efficacy, reduce systemic side effects, and increase patient compliance. Future research should focus on nanocarrier-based formulations, comprehensive in-vivo and clinical studies, long-term safety evaluation, and large-scale manufacturing to facilitate successful clinical translation of this promising drug delivery approach.

References

[1]. Alzheimer's Association. *2024 Alzheimer's Disease Facts and Figures*. Alzheimer's & Dementia. 2024; 20(5):3708–3821.

[2]. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. International Journal of Neuropsychopharmacology. 2006;9(1):101–124.

[3]. Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and

staying on. Current Therapeutic Research. 2003;64(4):216–235.
[4]. Pardridge WM. Drug transport across the blood–brain barrier. Journal of Cerebral Blood Flow & Metabolism. 2012;32(11):1959–1972.
[5]. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 2016;8(6):595–608.
[6]. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Molecular Neurodegeneration. 2019; 14:32.
[7]. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. Journal of Neurology, Neurosurgery & Psychiatry. 1999;66(2):137–147.
[8]. Polinsky RJ. Clinical pharmacology of Rivastigmine. Clinical Therapeutics. 1998;20(4):634–647.
[9]. Grossberg GT, Manes F. Rivastigmine: A review of its pharmacological properties and therapeutic efficacy. Clinical Interventions in Aging. 2010;5:93–104.
[10]. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2022. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2022; 8:e12295.
[11]. Illum L. Nasal drug delivery—possibilities, problems and solutions. Journal of Controlled Release. 2003;87(1–3):187–198.
[12]. Djupesland PG. Nasal drug delivery devices: characteristics and performance. Drug Delivery and Translational Research. 2013;3(1):42–62.
[13]. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Advanced Drug Delivery Reviews. 2012;64(7):614–628.
[14]. Pardridge WM. Drug transport across the blood–brain barrier. Journal of Cerebral Blood Flow & Metabolism. 2012;32(11):1959–1972.
[15]. Ruel-Gariépy E, Leroux JC. In situ-forming hydrogels—review of temperature-sensitive systems. European Journal of Pharmaceutics and Biopharmaceutics. 2004;58(2):409–426.
[16]. Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2009;71(3):505–518.
[17]. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of Poloxamer 407 pharmaceutical and pharmacological characteristics. Pharmaceutical Research. 2006;23(12):2709–2728.
[18]. Smart JD. The basics and underlying mechanisms of mucoadhesion. Advanced Drug Delivery Reviews. 2005;57(11):1556–1568.
[19]. Miyazaki S, Kawasaki N, Kubo W, Endo K, Attwood D. In situ gelling gellan formulations as vehicles for oral drug delivery. Journal of Controlled Release. 2001;67(2–3):275–280.
[20]. Andrews GP, Laverty TP, Jones DS. European Journal of Pharmaceutics and Biopharmaceutics. 2009;71:505–518.
[21]. Dumortier G, et al. Pharmaceutical Research. 2006;23:2709–2728.
[22]. Smart JD. Advanced Drug Delivery Reviews. 2005;57:1556–1568.
[23]. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 8th ed. Pharmaceutical Press; 2017.
[24]. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharmaceutical Research. 1998; 15:1326–1331.
[25]. Miyazaki S, et al. Journal of Controlled Release. 2001;67:275–280.
[26]. Yu LX. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control. Pharmaceutical Research. 2008;25(4):781–791.
[27]. Montgomery DC. Design and Analysis of Experiments. 10th ed. John Wiley & Sons; 2020.
[28]. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. Journal of Pharmacy and Pharmacology. 2001;53(1):3–21.
[29]. Illum L. Nasal drug delivery—possibilities, problems and solutions. Journal of Controlled Release. 2003;87(1–3):187–198.
[30]. International Council for Harmonisation (ICH). ICH Q1A(R2): Stability Testing of New Drug Substances and Products. 2003.
[31]. Higuchi T. Mechanism of sustained-action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. Journal of Pharmaceutical Sciences. 1963;52(12):1145–1149.
[32]. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. International Journal of Pharmaceutics. 1983;15(1):25–35.
[33]. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharmaceutica. 2010;67(3):217–223.
[34]. Khan S, et al. Recent advances in intranasal delivery of Rivastigmine for Alzheimer's disease. *International Journal of Pharmaceutics.* 2024.
[35]. Illum L. Nasal drug delivery—possibilities, problems and solutions. Journal of Controlled Release. 2003;87(1–3):187–198.
[36]. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Advanced Drug Delivery Reviews. 2005;57(11):1640–1665.
[37]. Djupesland PG. Nasal drug delivery devices: characteristics and performance. Drug Delivery and Translational Research. 2013;3(1):42–62.
[38]. Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Research Bulletin. 2018;143:155–170.